Tirzepatide vs Semaglutide: Mechanism, Results, and Side Effects

Key takeaways

• Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist, which is the core mechanistic difference between the two molecules.
• In the SURMOUNT-1 trial, tirzepatide produced mean weight loss of about 20.9% at the highest dose over 72 weeks in adults with obesity without type 2 diabetes.
• In the STEP-1 trial, semaglutide 2.4 mg produced mean weight loss of about 14.9% over 68 weeks in adults with obesity without type 2 diabetes.
• The SURMOUNT-5 head-to-head trial reported greater average weight reduction with tirzepatide than semaglutide 2.4 mg over 72 weeks in adults with obesity.
• Both drugs share a similar gastrointestinal side effect profile, including nausea, diarrhea, constipation, and a boxed warning for thyroid C-cell tumors based on rodent studies.
• Only a licensed prescriber can determine whether tirzepatide, semaglutide, or neither is appropriate for an individual patient.

Why this comparison matters

Tirzepatide and semaglutide are the two molecules behind the most-prescribed weight loss and type 2 diabetes injections in the United States. Semaglutide is the active ingredient in and , while tirzepatide is the active ingredient in and . Patients searching for one drug almost always end up comparing them to the other, because clinicians, pharmacists, and insurers routinely discuss the two together.

The two drugs are often grouped under the umbrella term 'GLP-1 medications,' but that label is technically incomplete. Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. That single mechanistic distinction drives most of the differences you will read about below, including average weight loss percentages, A1C reductions, and the side effect profile reported in major trials.

This article is strictly informational. GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. Nothing here is a recommendation that any specific person should take either drug. Only a licensed prescriber who knows your medical history can determine whether tirzepatide, semaglutide, both, or neither is appropriate for you.

Mechanism: single vs dual incretin agonism

Both molecules belong to the broader incretin family. Incretins are gut hormones released after meals that help regulate blood glucose, insulin secretion, glucagon suppression, and the rate at which the stomach empties. The two best-studied incretins are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Native versions of these hormones break down within minutes, so drug developers engineered long-acting analogs that resist that breakdown.

Semaglutide is a structurally modified analog of human GLP-1. It binds only to the GLP-1 receptor, where it stimulates glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain to reduce hunger. According to the FDA prescribing information for Wegovy and Ozempic, the half-life is approximately one week, which is why it is dosed as a once-weekly subcutaneous injection.

Tirzepatide is a single peptide molecule that activates both the GLP-1 receptor and the GIP receptor. This dual mechanism is novel — it is the first approved drug in this class. Activating GIP in addition to GLP-1 is thought to contribute to greater effects on insulin sensitivity, lipid handling, and appetite regulation, although the exact contribution of GIP agonism in humans is still being studied. The FDA labels for Mounjaro and Zepbound describe a similar once-weekly subcutaneous dosing schedule.

FDA-approved uses and brand mapping

Both molecules are approved by the FDA for different but overlapping indications. Knowing which brand corresponds to which indication helps patients understand insurance denials, off-label prescribing, and why the same active ingredient can appear under two different brand names with very different pricing.

Semaglutide is marketed as for type 2 diabetes (subcutaneous), Rybelsus for type 2 diabetes (oral tablet), and for chronic weight management in adults and adolescents who meet specific BMI criteria. Tirzepatide is marketed as for type 2 diabetes and for chronic weight management and, more recently, moderate-to-severe obstructive sleep apnea in adults with obesity, per the Zepbound FDA label update.

Doses and titration schedules differ between the diabetes indication and the obesity indication for the same molecule. Maximum approved doses are generally higher for the obesity indication. Your prescriber will determine the appropriate starting dose, titration speed, and maintenance dose based on your medical history, tolerance, and treatment goals. Do not assume the dose listed online for one indication applies to another.

Head-to-head trial data

Each drug has its own pivotal trial program. Semaglutide for obesity was studied in the STEP program (STEP-1 through STEP-8 and beyond). Tirzepatide for obesity was studied in the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5). Semaglutide for type 2 diabetes was studied in the SUSTAIN program, and tirzepatide for type 2 diabetes was studied in the SURPASS program. The most direct comparison comes from SURMOUNT-5, which randomized patients with obesity to either tirzepatide or semaglutide 2.4 mg.

In STEP-1, adults with obesity but without type 2 diabetes who received semaglutide 2.4 mg lost about 14.9% of body weight on average over 68 weeks, compared with about 2.4% in the placebo group, according to the New England Journal of Medicine publication. In SURMOUNT-1, adults with obesity but without type 2 diabetes who received the highest tirzepatide dose lost about 20.9% of body weight over 72 weeks, compared with about 3.1% in the placebo group.

SURMOUNT-5 was the first major head-to-head trial. Reported results showed greater average weight loss with tirzepatide than with semaglutide 2.4 mg over 72 weeks in adults with obesity, with a difference of several percentage points. Individual response varied considerably, and a subset of patients in both arms lost less than the average. Trial averages do not predict individual outcomes — that is why prescribers emphasize personalized monitoring.

Side effects and tolerability

Both drugs share a similar overall safety and side effect profile because both heavily involve GLP-1 signaling, which slows gastric emptying and acts on brain centers regulating nausea and appetite. The most common adverse events in trials for both drugs were gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Most of these events were mild to moderate, occurred during dose escalation, and tended to decline over time.

More serious risks listed on the FDA labels for both molecules include pancreatitis, gallbladder disease, acute kidney injury related to dehydration from severe vomiting or diarrhea, hypoglycemia (mainly when combined with insulin or sulfonylureas), and diabetic retinopathy complications in patients with pre-existing retinopathy. Both molecules carry a boxed warning about thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Discontinuation rates due to gastrointestinal side effects in pivotal trials were broadly similar across the two molecules, although exact rates depend on dose, titration speed, and patient population. If side effects are severe, your prescriber may slow titration, pause therapy, or switch you to a different medication. Never stop or adjust dosing on your own without contacting your prescriber.

Cardiovascular and cardiometabolic outcomes

Semaglutide has the most mature cardiovascular outcome data of the two. The SUSTAIN-6 trial in adults with type 2 diabetes showed a reduction in major adverse cardiovascular events with semaglutide compared with placebo. The SELECT trial, published in the New England Journal of Medicine, reported that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes, leading to an FDA label expansion for Wegovy.

Tirzepatide cardiovascular outcome data is still maturing. The SURPASS-CVOT trial, designed to evaluate cardiovascular outcomes in adults with type 2 diabetes and established cardiovascular disease, is comparing tirzepatide against an active GLP-1 comparator rather than placebo. Until those results are fully reported and reviewed, tirzepatide does not have an FDA-approved cardiovascular risk reduction indication equivalent to Wegovy's. This is an important distinction for patients whose primary goal is cardiovascular protection.

Both drugs improve cardiometabolic markers in trials: blood pressure, lipid panels, fasting glucose, A1C, and waist circumference all tend to improve alongside weight loss. The size of those improvements varies by patient, by dose, and by baseline values. Discuss with your prescriber which markers matter most for your situation.

Compounded versions: what to know

During periods when brand-name supplies were constrained, US compounding pharmacies produced and . These compounded products are not the same as the FDA-approved brand-name finished drugs. Compounded versions are prepared by licensed pharmacies under different regulatory rules and are not FDA-approved as finished products. Compounded versions have not been evaluated by the FDA for safety, efficacy, or manufacturing quality in the same way as Ozempic, Wegovy, Mounjaro, or Zepbound.

Compounded medications can be prescribed legally in specific circumstances under Sections 503A and 503B of the federal Food, Drug, and Cosmetic Act. However, the FDA has issued warnings about adverse events, dosing errors, and counterfeit ingredients tied to some compounded GLP-1 products. The FDA has also published guidance about when compounding is permitted as official shortages resolve. Patients considering compounded versions should ask the prescribing clinic about the source pharmacy, the form of the active ingredient, and the testing performed.

GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. If you are weighing a compounded versus brand product, that conversation belongs with your prescriber, not with marketing material. Pricing differences alone are not a sufficient reason to choose a compounded version.

Who is each drug studied for?

Pivotal trials enrolled specific populations, and trial averages apply most cleanly to people similar to those enrolled. STEP-1 enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity, who did not have type 2 diabetes. STEP-2 enrolled adults with type 2 diabetes and overweight or obesity. SURMOUNT-1 used similar BMI thresholds without type 2 diabetes; SURMOUNT-2 included participants with type 2 diabetes.

Most trials excluded people with a recent history of severe gastrointestinal disease, pancreatitis, certain thyroid cancers, end-stage kidney or liver disease, active malignancy, pregnancy, or several psychiatric conditions. Adolescent extensions for both drugs exist (STEP-TEENS for semaglutide, SURMOUNT-ADOLESCENTS for tirzepatide), but the FDA-approved age ranges differ. Older adults, patients with frailty, and patients with prior bariatric surgery are underrepresented in most pivotal trials.

If you do not fit the trial population, your prescriber will weigh the trial averages against your individual risk profile. That is normal clinical practice. The percentages from STEP and SURMOUNT are population-level averages, not personal forecasts.

Cost, access, and insurance

List prices for brand-name semaglutide and tirzepatide are similar in the US, both running over $1,000 per month at full cash price for the obesity indications, according to manufacturer-published prices and major pharmacy benefit data. Insurance coverage varies dramatically by plan: Medicare Part D historically excluded coverage for weight loss medications, though policy around obesity coverage continues to evolve. Coverage for the diabetes indications (Ozempic, Mounjaro) is generally broader.

Manufacturer savings programs exist for both molecules and can reduce out-of-pocket cost for commercially insured patients meeting eligibility criteria. Some compounded versions are sold cash-pay through telehealth clinics at significantly lower monthly prices. As noted earlier, those are not FDA-approved finished products and should be evaluated with a prescriber.

When comparing affordability, look beyond the headline monthly figure. Consider titration schedules, expected duration of therapy, the cost of side effect management, and whether your insurer requires prior authorization or step therapy with a different drug first. Your prescriber and your pharmacy can help you navigate this paperwork.

How to think about choosing — and why we will not choose for you

Reading trial averages is useful context, but choosing between tirzepatide and semaglutide is a clinical decision that should sit with a licensed prescriber. The clinician will weigh your weight loss goals, A1C if diabetes is involved, cardiovascular history, kidney function, thyroid history, gastrointestinal history, current medications, insurance coverage, and your personal preferences about injection frequency and side effect tolerance.

Some patients will respond better to tirzepatide; some will respond better to semaglutide; some will do equally well on either; some will not tolerate either. The published averages cannot tell you which group you fall into in advance. That is why both labels emphasize ongoing monitoring rather than a fixed maintenance plan.

GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers. The job of this article is to summarize what the trials say so you can have a more informed conversation with your prescriber, not to recommend a specific drug, dose, or provider.

Frequently asked questions

Is tirzepatide more effective than semaglutide for weight loss?

Average weight loss in the SURMOUNT-5 head-to-head trial was greater with tirzepatide than with semaglutide 2.4 mg over 72 weeks in adults with obesity. However, individual results vary widely, and trial averages do not predict how any single patient will respond. Your prescriber is best positioned to weigh efficacy data against your medical history and treatment goals.

Are tirzepatide and semaglutide the same drug class?

They are related but not identical. Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. Both are sometimes loosely grouped under 'GLP-1 medications,' but the dual GIP plus GLP-1 mechanism of tirzepatide is distinct and is a newer pharmacological approach.

Do tirzepatide and semaglutide have the same side effects?

The most common side effects overlap heavily and are mostly gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, especially during dose escalation. Both drugs also carry a boxed warning about thyroid C-cell tumors based on rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Your prescriber can discuss your specific risk profile.

Can I switch from semaglutide to tirzepatide or vice versa?

Switching is a clinical decision that requires evaluation of your current dose, response, side effects, and reason for switching. Patients sometimes switch because of tolerability, plateau in weight loss, insurance changes, or supply issues. Only a licensed prescriber can determine an appropriate transition schedule. Do not change medications on your own without medical guidance.

Is one drug safer than the other for the heart?

Semaglutide has more mature cardiovascular outcome data. The SELECT trial supported an FDA label expansion for Wegovy to include cardiovascular risk reduction in specific patient groups. Tirzepatide cardiovascular outcome data from SURPASS-CVOT is still maturing, and tirzepatide does not currently have an equivalent cardiovascular risk reduction indication. Your prescriber will weigh this in cases where heart protection is a primary goal.

Are compounded versions equivalent to brand-name tirzepatide or semaglutide?

No. Compounded semaglutide and compounded tirzepatide are not FDA-approved as finished products. They are prepared by licensed pharmacies under different regulatory rules than the FDA-approved brand drugs. The FDA has issued warnings about adverse events and dosing errors with some compounded GLP-1 products. Discuss any compounded option with your prescriber before starting.

Which brand contains tirzepatide and which contains semaglutide?

Tirzepatide is the active ingredient in Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and a newer obstructive sleep apnea indication). Semaglutide is the active ingredient in Ozempic (type 2 diabetes), Rybelsus (oral type 2 diabetes), and Wegovy (chronic weight management, including a cardiovascular risk reduction indication in specific groups).